Crixivan
indinavir
Table of contents
Overview
The marketing authorisation for Crixivan has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Crixivan
|
| Agency product number |
EMEA/H/C/000128
|
| Active substance |
indinavir sulfate ethanolate
|
| International non-proprietary name (INN) or common name |
indinavir
|
| Therapeutic area (MeSH) |
HIV Infections
|
| Anatomical therapeutic chemical (ATC) code |
J05AE02
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Merck Sharp & Dohme B.V.
|
| Revision |
39
|
| Date of issue of marketing authorisation valid throughout the European Union |
04/10/1996
|
| Contact address |
Waarderweg 39 |
Product information
03/08/2018 Crixivan - EMEA/H/C/000128 - T/0104
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antivirals for systemic use
Therapeutic indication
Crixivan is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults.